CARGO TherapeuticsCRGX
CRGX
About: Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
Employees: 167
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
400% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 5
124% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 17
75% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 7 (+3) [Q4]
25% more funds holding
Funds holding: 79 [Q3] → 99 (+20) [Q4]
15.75% more ownership
Funds ownership: 101.95% [Q3] → 117.7% (+15.75%) [Q4]
10% less capital invested
Capital invested by funds: $865M [Q3] → $781M (-$83.9M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
35%
downside
Avg. target
$4.67
2%
upside
High target
$7
53%
upside
3 analyst ratings
0 positive
0%
3 neutral
100%
0 negative
0%
Truist Securities Asthika Goonewardene 22% 1-year accuracy 5 / 23 met price target | 53%upside $7 | Hold Downgraded | 30 Jan 2025 |
Piper Sandler Biren Amin 19% 1-year accuracy 5 / 26 met price target | 13%downside $4 | Neutral Downgraded | 30 Jan 2025 |
Jefferies Michael Yee 22% 1-year accuracy 2 / 9 met price target | 35%downside $3 | Hold Downgraded | 30 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
CARGO Therapeutics Provides Corporate Update
- Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value - - CARGO had cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024 - - Anup Radhakrishnan appointed as interim CEO to pursue reverse merger or other business combination - SAN CARLOS, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX) today provided an update regarding its ongoing evaluation of strategic options following the discontinuation of FIRCE-1, a Phase 2 study of firicabtagene autoleucel (firi-cel).
Neutral
Accesswire
1 month ago
An Investigation Has Commenced on Behalf of CARGO Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CRGX Losses.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
Neutral
Accesswire
1 month ago
Lost Money on CARGO Therapeutics, Inc.(CRGX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / March 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
Neutral
Accesswire
1 month ago
An Investigation Has Been Launched Into CARGO Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 month ago
CARGO Therapeutics, Inc. (CRGX) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESS Newswire / March 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
Neutral
Accesswire
1 month ago
The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX
NEW YORK CITY, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("Cargo" or the "Company") (NASDAQ:CRGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
1 month ago
Levi & Korsinsky Reminds Shareholders of an Investigation into CARGO Therapeutics, Inc. (CRGX) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
Neutral
Accesswire
1 month ago
An Investigation Has Been Launched Into CARGO Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 month ago
CRGX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by CARGO Therapeutics, Inc.
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
Charts implemented using Lightweight Charts™